Conmed Corporation (NYSE: CNMD) has announced its preliminary financial information for the third quarter of 2024. The company expects revenue to be in the range of $315 million to $318 million, indicating a significant increase from the previous period. Additionally, Conmed anticipates adjusted diluted net earnings per share growth that exceeds its previously provided guidance of 9% to 11%.
Conmed will release its full financial results for the third quarter of 2024 after the market close on Wednesday, October 30, 2024. The company's management will host a conference call at 4:30 p.m. ET on the same day to discuss the results.
This preliminary financial information is subject to completion and has been prepared in good faith on a consistent basis with prior periods. However, the company has not completed its financial closing procedures for the period ended September 30, 2024, and its actual results could differ materially from this preliminary financial information. Therefore, prospective investors should exercise caution in relying on this information.
Conmed Corporation is a medical technology company that provides devices and equipment for surgical procedures in various specialties, including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology. As a result of these announcements, the company's shares have moved -0.5% on the market, and are now trading at a price of $66.25. If you want to know more, read the company's complete 8-K report here.
